MetaCap

Precigen (PGEN) vs Sarepta Therapeutics (SRPT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Precigen (PGEN) has outperformed Sarepta Therapeutics (SRPT) over the past year, gaining 8.5% versus a loss of 24.6%. Over five years, PGEN leads with a +9.1% price change compared with -83.3% for SRPT. Precigen is the larger company by market cap ($1.51 billion vs $1.43 billion), about 1.1 times the size.

On valuation, Precigen trades at a lower trailing P/E (38.3x vs 666.5x for Sarepta Therapeutics). Sarepta Therapeutics converts more of its revenue into profit, with a net margin of -32.5% versus -2588.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PGEN+8.51%SRPT-24.65%
+128%+48%-32%
Nov 21, 20251 yearNov 20, 2026
PGEN+11.97%SRPT-83.34%
+138%+21%-96%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PGEN versus SRPT key metrics
MetricPGENSRPT
Share price$4.21$13.33
Market cap$1.51B$1.43B
1-day change+1.20%-5.93%
YTD return+0.72%-38.06%
1-year return+8.51%-24.65%
5-year return+9.07%-83.26%
P/E ratio (TTM)38.27666.50
Forward P/E—8.87
EPS (TTM)$0.11$0.02
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$9.68M$2.20B
Revenue growth (YoY)+146.73%+15.58%
Net income (latest FY)$-250.64M$-713.41M
Gross margin—98.84%
Operating margin-1141.13%-31.83%
Net margin-2588.21%-32.45%
52-week high$8.98$24.68
52-week low$3.04$13.25
Distance from 52-week high-53.12%-45.99%
Analyst consensusbuyhold
Avg. price target upside+224.70%+63.32%
Average volume5.68M2.70M
Shares outstanding358.55M107.24M
Employees160835
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PGEN has outperformed SRPT by 33.2 percentage points over the past year.
  • Sarepta Therapeutics trades at a higher earnings multiple (666.5x vs 38.3x trailing P/E).
  • Sarepta Therapeutics is more profitable, keeping -32.5 cents of every revenue dollar as net income versus -2588.2 cents for Precigen.
  • Precigen grew revenue faster in its latest fiscal year (+146.73% vs +15.58%).

About Precigen

PGEN stock →

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees

About Sarepta Therapeutics

SRPT stock →

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.

Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees

PGEN vs SRPT FAQ

Which is bigger, Precigen or Sarepta Therapeutics?

Precigen (PGEN) is larger, with a market capitalization of $1.51B compared with $1.43B for Sarepta Therapeutics (SRPT).

Which stock has performed better over the past year, PGEN or SRPT?

PGEN returned +8.51% over the past 12 months, compared with -24.65% for SRPT (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, PGEN or SRPT?

PGEN has the lower trailing P/E at 38.3, versus 666.5 for SRPT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Precigen and Sarepta Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons